An interventional study of "Exercise for Muscle Health" Program in Sarcopenia and Breast Cancer, sponsored by Capital Medical University. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Capital Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Sarcopenia with a site in China — 47 open to participants now, 52 under way, 4 of them phase 3. Sarcopenia · China.
Among the 83 studies in Sarcopenia with a site in China, this one is the 28th largest by planned enrollment of the 52 interventional ones that give a count, is one of 16 that started in 2026, is one of 42 with no phase, reaches primary completion later than 29 of the 51 other live ones, and was the 77th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →47 of the 83 studies in Sarcopenia with a site in China are open now. Recruiting first, the newest first:
Shanghai Yueyang Integrated Medicine Hospital · Sites in China
Ages 60–90
Hangzhou PhecdaMed Co., Ltd. · Sites in China
Ages 60+
GuangZhou Cellgenes Biotechnology Co., Ltd. · Sites in China
Ages 50–85
Peking Union Medical College Hospital · Sites in China
Ages 18+
China Medical University, China · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 3
First in 2012; this study’s year is marked. 16 started in 2026.
This study's planned enrollment of 104 is above the median of 60 across 860 interventional studies indexed under Sarcopenia.
Median enrollment 110 across the 52 interventional studies, 868 across the 31 observational. Of the 25 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 83 have an industry lead sponsor. The 10 most frequent:
Capital Medical University is the lead sponsor of 296 studies on the registry; 90 are open to participants now.
Capital Medical University has 2 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
14 of the studies in Sarcopenia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07950150The Hong Kong Polytechnic UniversityPomegranate-Prebiotic Supplementation for Sarcopenic Obesity | 2026-12 |
| NCT07049731Weiwei MaImprovement of Skeletal and Muscle Health in Patients With Sarcopenia by Protein Powder With Resistance Exercise | 2026-12 |
| NCT07724587Ningbo Medical Center Lihuili HospitalThe Effectiveness and Safety of Combined Research on Uremic Sarcopenia | 2026-12-01 |
| NCT07059871Zhejiang HospitalA Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease. | 2026-12-30 |
| NCT07538674Shanghai Yueyang Integrated Medicine HospitalPeiyuan Guben Tongluo Ointment for Elderly Sarcopenia | 2027-03-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 83 studies in Sarcopenia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sarcopenia is a common yet underrecognized complication in breast cancer survivors during rehabilitation, characterized by loss of muscle mass, reduced muscle strength, and impaired physical function, which adversely affects quality of life and long-term outcomes. Exercise has been identified as a promising non-pharmacological intervention for sarcopenia; however, evidence-based exercise programs specifically tailored for breast cancer patients with sarcopenia remain limited.
This study aims to develop and evaluate a 12-week exercise intervention program ("Exercise for Muscle Health") for breast cancer patients with sarcopenia during rehabilitation. A randomized controlled trial will be conducted to assess the effectiveness of the intervention. A total of 104 eligible participants will be randomly assigned in a 1:1 ratio to either the intervention group or the control group. The intervention group will receive a 12-week structured exercise program combined with health education, while the control group will receive routine rehabilitation care with general physical activity recommendations.
The primary outcomes include changes in appendicular skeletal muscle mass index (ASMI), handgrip strength, Short Physical Performance Battery (SPPB) score, and physical fitness (2-Minute Step Test and 30-second Chair-Stand Test). Secondary outcomes include sarcopenia-related knowledge, cancer self-efficacy, social support, anxiety, fatigue, and quality of life. Assessments will be conducted at baseline (T0), mid-intervention (week 6, T1), immediately post-intervention (week 12, T2), and 3 months post-intervention (T3).
The hypothesis is that the 12-week "Exercise for Muscle Health" program will significantly improve muscle mass, muscle strength, and physical function compared to routine care, and will be feasible, acceptable, and safe for breast cancer patients with sarcopenia during rehabilitation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female, aged ≥18 years;
confirmed diagnosis of breast cancer, having completed primary treatment (surgery, chemotherapy, radiotherapy, etc.) and currently in the rehabilitation phase (≥3 months after treatment completion);
Meet sarcopenia diagnostic criteria assessed by trained researchers: for women aged ≥65 years, ASMI \< 0.57 and handgrip strength \< 18 kg; for women aged \<64 years, ASMI \< 0.63 and handgrip strength \< 20 kg;
Provide and voluntarily participate in the study;
Have basic communication and comprehension abilities.
Exclusion Criteria:
History of psychiatric disorders or consciousness impairment;
Presence of exercise including severe cardiac, hepatic, or renal insufficiency, bone , or uncontrolled hypertension;
Major surgery or severe trauma within the past 3 months;
Involuntary weight loss >5% within the past 3 months, or presence of active progressive tumor burden (e.g., imaging evidence of significant metastasis or receiving palliative chemotherapy), suggesting tumor-driven cachexia;
Currently participating in other exercise intervention studies or having completed other exercise programs within the past 6 months;
Refusal of randomization.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 12-week structured exercise intervention program consisting of two components: (1) Health education ; (2) Exercise intervention. The intervention is delivered by trained exercise specialists and supervised by the research team. Participants receive exercise diaries to record adherence.
Behavioral: "Exercise for Muscle Health" Program
Participants receive routine rehabilitation care for breast cancer survivors, including: (1) Health education: provision of a breast cancer rehabilitation knowledge booklet covering lymphedema prevention, balanced diet, and weight management; (2) General physical activity advice: recommendation to engage in at least 150 minutes of moderate-intensity aerobic exercise (such as walking) per week, without provision of structured exercise prescriptions, standardized exercise instruction, intensity monitoring, or regular supervision.
Participants receive routine rehabilitation care for breast cancer survivors, including: (1) provision of a breast cancer rehabilitation knowledge booklet covering lymphedema prevention, balanced diet, and weight management; (2) general physical activity advice recommending at least 150 minutes of moderate-intensity aerobic exercise (such as walking) per week, without structured exercise prescriptions, standardized instruction, intensity monitoring, or regular supervision.
Change in Appendicular Skeletal Muscle Mass Index (ASMI)
Measured using InBody 120 body composition analyzer via bioelectrical impedance analysis (BIA). ASMI is calculated as appendicular skeletal muscle mass (kg) divided by BMI (kg/m²).
Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)
Handgrip Strength
Measured using CAMRY electronic handgrip dynamometer (Model EH101). Participants stand with arms naturally, maximal grip strength is recorded twice for each hand, and the maximum value is used.
Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)
Short Physical Performance Battery (SPPB) Score
SPPB assesses lower extremity function through three tests: balance test (side-by-side, semi-tandem, and tandem stands), 4-meter gait speed test, and 5-repetition chair-stand test. Total score ranges from 0 to 12, with higher scores indicating better physical function.
Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)
Physical Fitness
Assessed by 2-Minute Step Test (2-MST) measuring cardiorespiratory endurance and 30-second Chair-Stand Test (CST) measuring lower limb muscle strength.
Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)
Sarcopenia Disease Knowledge
Measured using the Sarcopenia Disease Knowledge Scale developed by Tang et al. (2023), a self-reported 18-item scale covering etiology, clinical manifestations, hazards, diagnosis, and treatment. Likert 5-point scoring, higher scores indicate better knowledge.
Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)
Cancer Self-Efficacy
Measured using the Chinese version of the Strategies Used by People to Promote Health (SUPPH), a 28-item self-reported scale. Higher scores indicate greater self-efficacy in cancer self-management.
Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)
Social Support
Measured using the Social Support Rating Scale (SSRS) developed by Xiao Shuiyuan, a 10-item scale with three dimensions: objective support, subjective support, and utilization of support. Total score ranges from 12 to 66, with higher scores indicating higher social support.
Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)
Anxiety
Measured using the Generalized Anxiety Disorder-7 (GAD-7) scale, a 7-item self-reported scale. Total score ranges from 0 to 21, with higher scores indicating more severe anxiety.
Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)
Cancer-Related Fatigue
Measured using the Cancer Fatigue Scale (CFS), a 15-item scale with three dimensions: physical fatigue (7 items), affective fatigue (4 items), and cognitive fatigue (4 items). Likert 4-point scoring, total score ranges from 0 to 60
Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)
Change in Quality of Life
Measured using the 36-item Short-Form Health Survey (SF-36), Chinese version. Eight dimensions: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Each dimension scored 0-100, with higher scores indicating better health status.
Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)
Plan to share: No — Individual participant data (IPD) will not be shared with other researchers. This decision is based on the following considerations: (1) the informed consent form signed by participants does not include provisions for sharing individual-level data with external parties; (2) sharing of such data is restricted by China's Personal Information Protection Law to ensure strict protection of patient privacy; and (3) the study resources are insufficient to establish a secure public data repository for IPD.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.
Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 11 months is below that.
Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
Primary completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2027, last on Nov 17, 2026.
Completion moved twice since we started tracking on Sep 25, 2026: Apr 2027 → Aug 2027, last on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.